CL2013000655A1 - Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades. - Google Patents
Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades.Info
- Publication number
- CL2013000655A1 CL2013000655A1 CL2013000655A CL2013000655A CL2013000655A1 CL 2013000655 A1 CL2013000655 A1 CL 2013000655A1 CL 2013000655 A CL2013000655 A CL 2013000655A CL 2013000655 A CL2013000655 A CL 2013000655A CL 2013000655 A1 CL2013000655 A1 CL 2013000655A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- dihydrobenzoxathiazepines
- anxious
- alzheimer
- phenoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 102000003678 AMPA Receptors Human genes 0.000 title 1
- 108090000078 AMPA Receptors Proteins 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 title 1
- VTYQBIORYVOZDN-UHFFFAOYSA-N O(C1=CC=CC=C1)N1SOC2=C(CC1)C=CC=C2 Chemical class O(C1=CC=CC=C1)N1SOC2=C(CC1)C=CC=C2 VTYQBIORYVOZDN-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1003683A FR2964969B1 (fr) | 2010-09-16 | 2010-09-16 | Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000655A1 true CL2013000655A1 (es) | 2013-08-09 |
Family
ID=43067253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000655A CL2013000655A1 (es) | 2010-09-16 | 2013-03-08 | Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades. |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US8569285B2 (es) |
| EP (1) | EP2431360B1 (es) |
| JP (1) | JP2013537216A (es) |
| KR (1) | KR20130054438A (es) |
| CN (1) | CN103153973A (es) |
| AP (1) | AP2013006793A0 (es) |
| AR (1) | AR082973A1 (es) |
| AU (1) | AU2011213898A1 (es) |
| BR (1) | BR112013005967A2 (es) |
| CA (1) | CA2752131C (es) |
| CL (1) | CL2013000655A1 (es) |
| CO (1) | CO6680709A2 (es) |
| CR (1) | CR20130105A (es) |
| CU (1) | CU20130037A7 (es) |
| CY (1) | CY1114110T1 (es) |
| DK (1) | DK2431360T3 (es) |
| EA (1) | EA201300340A1 (es) |
| EC (1) | ECSP13012489A (es) |
| ES (1) | ES2421504T3 (es) |
| FR (1) | FR2964969B1 (es) |
| GE (1) | GEP20156247B (es) |
| GT (1) | GT201300067A (es) |
| HR (1) | HRP20130505T1 (es) |
| IL (1) | IL225209A0 (es) |
| MA (1) | MA34529B1 (es) |
| ME (1) | ME01524B (es) |
| MX (1) | MX2013002892A (es) |
| NI (1) | NI201300028A (es) |
| PE (1) | PE20131342A1 (es) |
| PL (1) | PL2431360T3 (es) |
| PT (1) | PT2431360E (es) |
| RS (1) | RS52835B (es) |
| SA (1) | SA111320755B1 (es) |
| SG (1) | SG188380A1 (es) |
| SI (1) | SI2431360T1 (es) |
| TW (1) | TWI421080B (es) |
| UA (1) | UA105320C2 (es) |
| UY (1) | UY33574A (es) |
| WO (1) | WO2012035216A1 (es) |
| ZA (1) | ZA201106353B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111559990B (zh) * | 2020-05-29 | 2021-03-09 | 四川大学华西医院 | 一种小分子噁噻嗪类衍生物及其应用 |
| CN111518058B (zh) * | 2020-05-29 | 2021-03-09 | 四川大学华西医院 | 一种噁噻嗪类化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2214405C2 (ru) * | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| TWI232863B (en) * | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
| MXPA03011562A (es) * | 2001-06-14 | 2004-03-18 | Akzo Nobel Nv | Derivados de (pirido/tieno)-(f)-oxazepin-5-ona como moduladores positivos del receptor ampa. |
| FR2856064B1 (fr) * | 2003-06-13 | 2005-08-19 | Servier Lab | Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
-
2010
- 2010-09-16 FR FR1003683A patent/FR2964969B1/fr not_active Expired - Fee Related
-
2011
- 2011-08-24 UY UY0001033574A patent/UY33574A/es unknown
- 2011-08-25 AU AU2011213898A patent/AU2011213898A1/en not_active Abandoned
- 2011-08-30 ZA ZA2011/06353A patent/ZA201106353B/en unknown
- 2011-09-07 CA CA2752131A patent/CA2752131C/fr not_active Expired - Fee Related
- 2011-09-07 TW TW100132314A patent/TWI421080B/zh not_active IP Right Cessation
- 2011-09-14 SA SA111320755A patent/SA111320755B1/ar unknown
- 2011-09-14 AR ARP110103332A patent/AR082973A1/es unknown
- 2011-09-15 SG SG2013015904A patent/SG188380A1/en unknown
- 2011-09-15 KR KR1020137009580A patent/KR20130054438A/ko not_active Application Discontinuation
- 2011-09-15 AP AP2013006793A patent/AP2013006793A0/xx unknown
- 2011-09-15 SI SI201130030T patent/SI2431360T1/sl unknown
- 2011-09-15 ME MEP-2013-82A patent/ME01524B/me unknown
- 2011-09-15 RS RS20130274A patent/RS52835B/en unknown
- 2011-09-15 ES ES11290413T patent/ES2421504T3/es active Active
- 2011-09-15 DK DK11290413.1T patent/DK2431360T3/da active
- 2011-09-15 GE GEAP201113048A patent/GEP20156247B/en unknown
- 2011-09-15 CN CN2011800437978A patent/CN103153973A/zh active Pending
- 2011-09-15 MX MX2013002892A patent/MX2013002892A/es active IP Right Grant
- 2011-09-15 JP JP2013528735A patent/JP2013537216A/ja active Pending
- 2011-09-15 PT PT112904131T patent/PT2431360E/pt unknown
- 2011-09-15 BR BR112013005967A patent/BR112013005967A2/pt not_active Application Discontinuation
- 2011-09-15 UA UAA201304534A patent/UA105320C2/ru unknown
- 2011-09-15 PE PE2013000377A patent/PE20131342A1/es not_active Application Discontinuation
- 2011-09-15 EP EP11290413.1A patent/EP2431360B1/fr active Active
- 2011-09-15 US US13/200,045 patent/US8569285B2/en not_active Expired - Fee Related
- 2011-09-15 WO PCT/FR2011/000502 patent/WO2012035216A1/fr active Application Filing
- 2011-09-15 MA MA35744A patent/MA34529B1/fr unknown
- 2011-09-15 EA EA201300340A patent/EA201300340A1/ru unknown
- 2011-09-15 PL PL11290413T patent/PL2431360T3/pl unknown
-
2013
- 2013-03-08 CL CL2013000655A patent/CL2013000655A1/es unknown
- 2013-03-11 CR CR20130105A patent/CR20130105A/es unknown
- 2013-03-12 CO CO13049160A patent/CO6680709A2/es not_active Application Discontinuation
- 2013-03-14 NI NI201300028A patent/NI201300028A/es unknown
- 2013-03-14 CU CU2013000037A patent/CU20130037A7/es unknown
- 2013-03-14 GT GT201300067A patent/GT201300067A/es unknown
- 2013-03-14 IL IL225209A patent/IL225209A0/en unknown
- 2013-03-15 EC ECSP13012489 patent/ECSP13012489A/es unknown
- 2013-06-07 HR HRP20130505AT patent/HRP20130505T1/hr unknown
- 2013-07-03 CY CY20131100553T patent/CY1114110T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000806A1 (es) | Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple. | |
| BR112013004766A2 (pt) | 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 | |
| CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| UY29079A1 (es) | Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| BR112012013431A2 (pt) | composto, composição farmacêutica e seu uso | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| UY29223A1 (es) | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación | |
| BR112014021531A2 (pt) | composto, composição farmacêutica e usos dos mesmos | |
| CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
| CL2007003733A1 (es) | Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi | |
| UY29839A1 (es) | Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones. | |
| CL2007002288A1 (es) | Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro | |
| CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
| BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
| EA201590562A1 (ru) | Бензамиды | |
| BR112014011981B8 (pt) | Formulações farmacêuticas sólidas orais, seus processos de preparação e usos | |
| CO7131369A2 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
| ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
| BR112012032721A2 (pt) | compostos heterocíclicos, sua preparação e sua aplicação terapêutica | |
| BR112015004306A2 (pt) | fluorometil-substituído pirrol carboxamidas |